Conclusion Mabthera was safe and effective for the treatment of elderly patients with AIHA.
结论美罗华治疗老年aiha患者安全、有效。
2
Objective To investigate the adverse reactions of rituximab (Rituxan and MabThera) in retrospection to provide references for safe and rational drug use clinically.
目的探讨抗肿瘤靶向药物利妥昔单抗（美罗华）不良反应的特点及规律，为临床安全、合理用药提供参考。
3
Conclusions: the combination of MabThera and CEOP regimen had high efficacy with mild toxicity in the treatment of aggressive B-cell lymphoma, hopefully may become the standard treatment.